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Introduction {#sec005}
============

Neuromyelitis optica (NMO) is a demyelinating inflammatory disorder of the central nervous system (CNS) that is clinically and pathologically defined as the co-occurrence of optic neuritis and myelitis \[[@pone.0152720.ref001], [@pone.0152720.ref002]\]. Aquaporin (AQP)4 is considered a potential autoantigen in patients with NMO after an autoantibody, designated NMO-IgG, that binds to human (h) AQP4 was detected in the serum of the vast majority of patients with NMO \[[@pone.0152720.ref003], [@pone.0152720.ref004]\]. The presence of the NMO-IgG has led many neurologist and neuroimmunologists to believe that NMO may be a primarily B cell-mediated disease.

However, there is evidence to suggest a cellular immune response in NMO during disease initiation or perpetuation \[[@pone.0152720.ref005], [@pone.0152720.ref006]\]. HLA haplotype analyses of patients with NMO suggest a positive association with *HLA-DRB1*\* *03*:*01* (DR17) \[[@pone.0152720.ref007], [@pone.0152720.ref008]\] \[[@pone.0152720.ref009]\], a gene that codes for a major histocompatibility class (MHC) II molecule that presents linear antigens to CD4^+^ T cells \[[@pone.0152720.ref010]\]. Also, NMO-IgG is undetectable in a substantial number of patients with NMO \[[@pone.0152720.ref003]\]. A NMO-IgG, antibody isotype switch from IgM to IgG could not occur without CD4^+^ T cell involvement \[[@pone.0152720.ref011], [@pone.0152720.ref012]\], which are abundantly present in NMO lesions \[[@pone.0152720.ref013]\]. B cell--depleting therapies are not consistently beneficial in patients with NMO \[[@pone.0152720.ref014]--[@pone.0152720.ref016]\]. Finally, transfer of AQP4-reactive T cells into wild-type mice and rats results in neurological deficits and CNS inflammation \[[@pone.0152720.ref017], [@pone.0152720.ref018]\].

Other investigators have identified immunogenic linear determinants in various rodent species \[[@pone.0152720.ref005], [@pone.0152720.ref006], [@pone.0152720.ref019]--[@pone.0152720.ref021]\]. We have previously shown that human AQP4 peptide 281--330 (hAQP4~281-300~) is the dominant immunogenic determinant of hAQP4 in the context of *HLA-DRB1*\**03:01 \[[@pone.0152720.ref021]\]*. Characterizing the encephalitogenic role of these AQP4 specific T helper cells will bring to light the role of the cellular immune response in the initiation and progression of the NMO clinical disease phenotype.

In this study we intended to establish a T cell-mediated animal model of NMO in the context of *HLA-DRB1\*03*:*01*, utilizing hAQP4~281-300~ as the dominant hAQP4 determinant in that MHC II haplotype. Induction of an autoimmune disorder resembling experimental autoimmune encephalomyelitis (EAE)\[[@pone.0152720.ref022]\] was attempted by active immunization and adoptive transfer. Clinical disease activity, CNS tissue inflammation, and changes in pupillary reflexes were assessed. Alanine scanning of AQP4~281-300~ was performed to test recognition by mouse T cell receptors (TCRs) and *HLA-DRB1\*03*:*01*.

We were unable to induce clinical EAE, CNS inflammation, or altered pupillary responses. Disease resistance is the result of a single amino acid substitution from aspartic acid in hAQP4 to glutamic acid in murine (m)AQP4 at position 290 prevents the recognition of hAQP4~281-300~ by the murine T cell receptor (TCR).

Results {#sec006}
=======

Immunization with human (h)AQP4~281-300~ leads to an expansion of antigen-specific CD4^+^ T cells in vivo {#sec007}
---------------------------------------------------------------------------------------------------------

Following immunization with human (h)AQP4~281-300~ an expansion of antigen-specific CD4^+^ T helper cells was detected by tetramer staining of lymph node cells (**[Fig 1A](#pone.0152720.g001){ref-type="fig"}**).

![Immunization with human (h)AQP4~281-300~ leads to an expansion of antigen-specific CD4^+^ T cells *in vivo*, and an Ig isotype switch in *HLA-DRB1\*03*:*01* transgenic mice.\
(A) Following immunization with human (h)AQP4~281-300~, an expansion of antigen-specific CD4^+^ T helper cells was detected by tetramer staining of lymph node cells. The fluorescent signal of *HLA-DRB1\*03*:*01*-loaded tetramers minus the fluorescent signal of empty *HLA-DRB1\*03*:*01* tetramers is shown. CD4^+^ T helper cells provide soluble mediators that drive B cell differentiation immunoglobulin (Ig) class switching. To determine whether hAQP4~281-300~-reactive CD4^+^ T cells are capable of causing IgM to IgG isotype switching in *HLA-DRB1\*03*:*01* transgenic mice, the concentration of Ig against hAQP4~281-300~, mAQP4284-299, or with whole-length hAQP4 protein in serum of immunized mice was quantified longitudinally. Since the NMO-IgG is a human IgG1 isotype, both, the murine IgG2a and IgG2b isotype were examined as they have similar properties with regard to complement binding and the Fcγ receptor. A switch from IgM to IgG2b was detected in mice immunized with hAQP4~281-300~ peptide with regard to (B) antibody responses against hAQP4~281-300~ and (C) whole-length AQP4 protein. An Ig isotype switch from IgM to IgG2b was also detectable in mice immunized with whole-length AQP4 protein with regard to (D) antibody responses against hAQP4~281-300~ and (E) whole-length AQP4 protein.](pone.0152720.g001){#pone.0152720.g001}

Immunization with human (h)AQP4~281-300~ leads to an Ig isotype switch in HLA-DRB1\*03:01 transgenic mice {#sec008}
---------------------------------------------------------------------------------------------------------

CD4^+^ T helper cells provide soluble mediators that drive B cell differentiation immunoglobulin (Ig) class switching. To determine whether hAQP4~281-300~-reactive CD4^+^ T cells are capable of causing IgM to IgG isotype switching in *HLA-DRB1\*03*:*01* transgenic mice, the concentration of Ig against hAQP4~281-300~, mAQP4284-299, or with whole-length hAQP4 protein in serum of immunized mice was quantified longitudinally. Since the NMO-IgG is a human IgG1 isotype, both, the murine IgG2a and IgG2b isotype were examined as they have similar properties with regard to complement binding and the Fcγ receptor. A switch from IgM to IgG2b was detected in mice immunized with hAQP4~281-300~ peptide with regard to antibody responses against hAQP4~281-300~ (**[Fig 1B](#pone.0152720.g001){ref-type="fig"}**), and whole-length AQP4 protein (**[Fig 1C](#pone.0152720.g001){ref-type="fig"}**). An Ig isotype switch from IgM to IgG2b was also detectable in mice immunized with whole-length AQP4 protein with regard to antibody responses against hAQP4~281-300~ (**[Fig 1D](#pone.0152720.g001){ref-type="fig"}**), and whole-length AQP4 protein (**[Fig 1E](#pone.0152720.g001){ref-type="fig"}**). Thus, B cells of *HLA-DRB1\*03*:*01 transgenic mice* are capable of recognizing hAQP4~281-300~ peptide via the B cell receptor (BCR), and the cellular immune response against hAQP4~281-300~ subsequently drives Ig isotype switching. These data support our previously published data that hAQP4~281-300~ is a dominant determinant in *HLA-DRB1\*03:01 \[[@pone.0152720.ref021]\]*.

Active immunization with hAQP4 does not lead to clinical disease {#sec009}
----------------------------------------------------------------

We first examined whether active immunization of *HLA-DRB1\*03*:*01* transgenic \[[@pone.0152720.ref023]\] mice with hAQP4 results in clinical disease. A multitude of experimental procedures and conditions were tested to examine the encephalitogenic potential of hAQP4 peptides using the transgenic mice. Previously, our laboratory determined that hAQP4~281-300~ was capable of generating a strong Th~1~ and Th~17~ immune response as measured by IFNγ and IL-17 ELISpot assay \[[@pone.0152720.ref021]\]. We performed active immunization with whole-length hAQP4 protein, hAQP4~281-300~, or mAQP4~281-300~ in an attempt to generate an animal model of NMO. Experimental animals also received intraperitoneal (i.p.) injections of pertussis toxin (Ptx) on the day of immunization and two days post immunization \[[@pone.0152720.ref024]\]. This approach resulted in no observable clinical paralysis commonly seen in EAE models (**[Fig 2A](#pone.0152720.g002){ref-type="fig"}**). Immunization with a positive control proteolipid protein (PLP)~91-110~, the dominant encephalitogenic determinant in *HLA-DRB1\*03*:*01* \[[@pone.0152720.ref025]\] led to typical EAE (**[Fig 2A](#pone.0152720.g002){ref-type="fig"}**). All EAE experiments were terminated at day 30. None of the experimental animals immunized with PLP~91-110~ that developed EAE died prematurely.

![*HLA-DRB1\*03*:*01* transgenic mice are disease resistant to active immunization with human aquaporin 4 (hAQP4), and adoptive transfer of hAQP4-specific T cells.\
(A) *HLA-DRB1\*03*:*01* mice were actively immunized with proteolipid protein (PLP)~91-110~ (100 μg/100 μl/mouse; positive control \[[@pone.0152720.ref025]\]), or varying AQP4 antigens\*(whole-length hAQP4 protein, hAQP4~281-300~, murine (m)AQP4~281-300~, hAQP4~281-300~ with a Quil-A Incomplete Freund Adjuvant (IFA) booster on day 14 post-immunization, mAQP4~281-300~ with a Quil-A IFA booster on day 14 post immunization, and hAQP4~281-300~ plus mAQP4~281-300~) emulsified in Complete Freund Adjuvant (CFA). Immunization with a positive control proteolipid protein (PLP)~91-110~, a dominant encephalitogenic determinant in *HLA-DRB1\*03*:*01* led to typical EAE. (B) Lymph node cells taken from *HLA-DRB1\*03*:*01* mice immunized with hAQP4~281-300~ or mAQP4~281-300~ were restimulated for three days and passively transferred into *HLA-DRB1\*03*:*01* mice. None of these experimental approaches resulted in clinical disease. (C) Paraffin sections were stained with haematoxlin eosin (H&E) and luxol fast blue (LFB). Representative sections of the spinal cords from PLP~91-110~ and hAQP4~281-300~ immunized mice are shown. On histopathological examination there were no visible signs of cellular infiltration, inflammation, or demyelination within the brain and spinal cord in any experimental paradigms other than in active immunization with PLP~91-110~, the dominant encephalitogenic determinant in *HLA-DRB1\*03*:*01* that led to typical EAE (spinal cord shown; inflammatory infiltrates and areas of demyelination are indicated by black arrows). (D) Fifteen days post immunization of *HLA-DRB1\*03*:*01* transgenic mice with PLP~91-110~ or hAQP4~281-300~, pupillary reflex was measured via a mouse pupillometry. Mice actively immunized with hAQP4~281-300~ and the control antigen PLP~91-110~ did not show altered pupillary responses.](pone.0152720.g002){#pone.0152720.g002}

Subsequently, alternative methods to generate a T cell-mediated NMO model were employed. Some CNS autoimmune disease animal models require weekly booster immunization to generate disease phenotypes \[[@pone.0152720.ref026]\]. The rationale for this approach is to increase the encephalitogenic potential of hAQP4~281-300~ by overcoming mechanisms of peripheral tolerance. In other experiments, additional booster immunization were given at day fourteen with adjuvants other than CFA, including QuilA and incomplete Freund's adjuvant (IFA)~.~ Again, no clinical disease was observed (**[Fig 2A](#pone.0152720.g002){ref-type="fig"}**).

Mice were also co-immunized mice with both hAQP4~281--300~ and mAQP4~281-300~. Again, there was complete disease resistance (**[Fig 2A](#pone.0152720.g002){ref-type="fig"}**).

Adoptive transfer of hAQP4281-300-specific CD4^+^ T cells does not lead to clinical disease {#sec010}
-------------------------------------------------------------------------------------------

In the adoptive transfer EAE model myelin-reactive activated CD4^+^ T cells are transferred into a naïve recipient. This model has some propensities that are very different from actively-induced EAE: \[[@pone.0152720.ref027]\] The potential effects of adjuvant and pertussis toxin on the innate immune system are eliminated, and \[[@pone.0152720.ref027]\] *in vitro* re-activated donor T cells are less dependent on reactivation within the recipient CNS \[[@pone.0152720.ref028]\]. This model was specifically developed to test the role of antigen-specific donor T cells in EAE pathogenesis \[[@pone.0152720.ref029]\]. Since Th~1~ and Th~17~ cells have been shown in the EAE model to be capable of causing disease when passively transferred, we next examined whether hAQP4~281-300~-specific T cells could cause disease via adoptive transfer. No disease phenotype was detected (**[Fig 2B](#pone.0152720.g002){ref-type="fig"}**). These results indicate that reactivation of hAQP4~281-300~--specific or mAQP4~281-300~--specific CD4^+^ Th~1~ cells does not occur in the CNS of *HLA-DRB1\*03*:*01* recipient mice.

On histopathological examination there were no visible signs of cellular infiltration, inflammation, or demyelination within the brain and spinal cord in any experimental paradigms other than in active immunization with PLP~91-110~, the dominant encephalitogenic determinant in *HLA-DRB1\*03*:*01* that led to typical EAE (spinal cord shown in **[Fig 2C](#pone.0152720.g002){ref-type="fig"}**; inflammatory infiltrates and areas of demyelination are indicated by black arrows). The absence of any functional deficits was further corroborated through measuring of the pupillary reflex by murine pupillometry on day 15 post immunization (**[Fig 2D](#pone.0152720.g002){ref-type="fig"}**). Mice did not show altered pupillary responses, further substantiating our previous findings that no functional or structural damage had occurred within the optic nerve.

The outcomes of these experiments suggested that mAQP4~281-300~ cannot be recognized in the context of *HLA-DRB1\*03*:*01*, or that hAQP~281-300~ cannot be recognized by B.10 TCR.

Single Amino Acid difference leads to blocking of hAQP4-mediated T cell proliferation and differentiation {#sec011}
---------------------------------------------------------------------------------------------------------

Within the immunogenic hAQP4~281-300~, there is a single amino acid mutation at position 290 between the human peptide and the mouse analog: An aspartic acid (D) in the human peptide to glutamic acid (E) in the mouse (**[Fig 3A](#pone.0152720.g003){ref-type="fig"}**). Both are negatively charged acidic amino acids that contain a carboxylic acid at the end of their side-chains. The difference between the two amino acids is an additional methyl group in the side chain of glutamic acid.

![Human (h)AQP4~281-300~-specific T cells do not cross-react with murine (m) AQP4~281-300.~\
(A) There is that a single amino acid substitution from aspartic acid in hAQP4 to glutamic acid in murine (m)AQP4 at position 290. (B) In lymph node cells of *HLA-DRB1\*03*:*01* mice immunized with hAQP4~281-300~ there was a significant proliferation of CD4^+^ T cells when hAQP4~281-300~ was used as the recall antigen (\* = P-value = 0.01). Only a higher recall antigen dose of 25 μg/ml resulted in a significant increase in proliferation, whereas as a dose of 5 μg/ml did not. (C) There was no proliferative response to mAQP4~281-300~ at either dose~.~ (D) There is a significantly increased frequency of IFNγ and IL-17 producing lymph nodes cells from *HLA-DRB1\*03*:*01* mice immunized with hAQP4~281-300~ by ELISpot assay when hAQP4~281-300~, and hAQP4~281-299~ are used as recall antigens. However, we were unable to detect antigen specific IFNγ and IL-17 producing lymph nodes cells when mAQP4~281-300~, or the negative control hAQP4~66-79~ were used as recall antigens (\*\* = P-value \< 0.01). (E) IFNγ and IL-17 producing lymph nodes cells from *HLA-DRB1\*03*:*01* mice immunized with mAQP4~281-300~ were undetectable with any of the recall antigens.](pone.0152720.g003){#pone.0152720.g003}

In lymph node cells of *HLA-DRB1\*03*:*01* mice immunized with hAQP4~281-300~ there was a significant proliferation of both CD4^+^ T cells when 25 μg/ml of hAQP4~281-300~ was used as the recall antigen (**[Fig 3B](#pone.0152720.g003){ref-type="fig"}**). A dose of 5 μg/ml hAQP4~281-300~, or mAQP4~281-300~ did not result in a significant proliferative response (**[Fig 3B](#pone.0152720.g003){ref-type="fig"}**). Lymph node cells of *HLA-DRB1\*03*:*01* mice immunized with mAQP4~281-300~ did also not proliferate in response to mAQP4~281-300~, or hAQP4~281-300~ at either dose (**[Fig 3C](#pone.0152720.g003){ref-type="fig"}**)~.~ An ELISpot assay revealed a significantly increased frequency of IFNγ and IL-17 producing lymph nodes cells from *HLA-DRB1\*03*:*01* mice immunized with hAQP4~281-300~ by ELISpot assay when hAQP4~281-300~ and hAQP4~284-299~ are used as recall antigens (**[Fig 3D](#pone.0152720.g003){ref-type="fig"}**). However, we were unable to detect antigen specific IFNγ and IL-17 producing lymph nodes cells when mAQP4~281-300~, or the negative control hAQP4~66-79~ were used as recall antigens. IFNγ and IL-17 producing lymph nodes cells from *HLA-DRB1\*03*:*01* mice immunized with mAQP4~281-300~ were undetectable with any of the recall antigens (**[Fig 3E](#pone.0152720.g003){ref-type="fig"}**).

Our observations suggest that the aspartic acid residue plays a critical role in either the presentation of hAQP4~281-300~ in the context of *HLA-DRB1\*03*:*01*, or in the recognition of hAQP4~281-300~ by the B.10 TCR.

hAQP4~281-300~ and mAQP4~281-300~ binds to the HLA-DRB1\*03:01 MHC II molecule {#sec012}
------------------------------------------------------------------------------

With no detectable cellular immune response against mAQP4~281-300~ in *HLA-DRB1\*03*:*01*, we next examined whether the single amino acid mutation affected the anchoring of the mouse peptide to the *HLA-DRB1\*03*:*01* molecule. To identify critical residues of the AQP4 peptides, alanine-scanning peptides were generated that replaced each amino acid of mAQP4~281-300~ with an alanine to aid in distinguishing anchor residues from contact residues (**[Table 1](#pone.0152720.t001){ref-type="table"}**). Since we previously identified hAQP4~284-299~ to be the immunogenic region within hAQP4~281-299~ \[[@pone.0152720.ref021]\], the alanine scanning peptides assessed only these residues.

10.1371/journal.pone.0152720.t001

###### Human (h)AQP4~284-299~ Alanine Scanning Peptides.

The immunogenic region of hAQP4~281-300~, hAQP4~284-299~, was utilized to generate alanine scanning peptides at which each peptide sequence has a single alanine residue mutation.

![](pone.0152720.t001){#pone.0152720.t001g}

  Peptide          Amino Acid Sequence
  ---------------- ----------------------
  Human 284--299   RSQVET**D**DLILKPGVV
  Mouse 284--299   RSQVET**E**DLILKPGVV
  R284A            **A**SQVETDDLILKPGVV
  S285A            R**A**QVETDDLILKPGVV
  Q286A            RS**A**VETDDLILKPGVV
  V287A            RSQ**A**ETDDLILKPGVV
  E288A            RSQV**A**TDDLILKPGVV
  T289A            RSQVE**A**DDLILKPGVV
  D290A            RSQVET**A**DLILKPGVV
  D291A            RSQVETD**A**LILKPGVV
  L292A            RSQVETDD**A**ILKPGVV
  I293A            RSQVETDDL**A**LKPGVV
  L294A            RSQVETDDLI**A**KPGVV
  K295A            RSQVETDDLIL**A**PGVV
  P296A            RSQVETDDLILK**A**GVV
  G297A            RSQVETDDLILKP**A**VV
  V298A            RSQVETDDLILKPG**A**V
  V299A            RSQVETDDLILKPGV**A**

First, the ability of hAQP4~281-300~-reactive lymph node cells to recognize the alanine screening peptides was determined by ELISpot (**[Fig 4A](#pone.0152720.g004){ref-type="fig"}**). Alanine screening peptides that not result in an increased frequency of IFNγ and IL-17 secreting lymph node cells were identified as the key residue peptides. Utilizing a flow-cytometry based MHC II binding assay, we were able to delineate between anchor residues and TCR contact residues. To perform the flow-cytometry based MHC II binding assay, peptides were biotinylated so that when presented in the context of *HLA-DRB1\*03*:*01*, a FITC-avidin would distinguish peptides that were capable of being presented from those that could not. In comparing the percent of FITC-avidin positive cells, amino acids 288E and 294L were identified as the main anchor residues that interact with the *HLA-DRB1\*03*:*01* MHC II molecule (**[Fig 4B](#pone.0152720.g004){ref-type="fig"}**). The remaining residues, including the 290D residue that distinguishes mAQP4~281-300~ and hAQP4~281-300~, were not required for binding. As a negative control, alanine scanning peptides were tested in C57BL/6 mice to examine the critical residues for binding to the *H-2b* MHC II molecule. Despite hAQP4~281-300~ being able to be presented on the *H-2b* MHC II molecule, the critical residues were not similar to the critical residues necessary for binding to the *HLA-DRB1\*03*:*01* MHC II molecule. This observation may explain why we were unable to elicit cellular immune response against hAQP4~281-300~ in C67BL/6 mice immunized with this peptide (data not shown).

![Identification of critical residues of human (h)AQP4~281-300~ for presentation in the context of *HLA-DRB1\*03*:*01* and recognition by the B.10 T cell receptor (TCR).\
(A) First, the ability of hAQP4~281-300~-reactive lymph node cells to recognize the alanine screening peptides was determined by ELISpot. 5.0x10^5^ cells/well lymph node cells taken ten days post immunization of *HLA-DRB1\*03*:*01* transgenic mice with hAQP4~281-300~ were restimulated with hAQP4 alanine scanning peptides (2 5 μg/mL) for 48 hours in IFNγ and IL-17 ELISpot plates (\* = P-value \< 0.05 and \*\* = P-value \< 0.01). (B) Alanine screening peptides that not result in an increased frequency of IFNγ and IL-17 secreting lymph node cells were identified as the key residue peptides, and were subsequently tested in a MHC binding assay. Splenocytes taken from *HLA-DRB1\*03*:*01* transgenic mice were incubated for 12 hours in the presence of biotinylated hAQP4 alanine scanning peptides. Post incubation, cells were stained utilizing FITC-Avidin, and antigen positive cells were quantified by flow cytometry (\* = P-value \< 0.05 and \*\* = P-value \< 0.01). (C) There was no Ig isotype class switch in mice immunized with mAQP4~284-299~ with regard to antibody responses against whole-length AQP4 protein. (D) Critical *HLA-DRB1\*03*:*01* anchor residues, and B.10 TCR contact amino acids are specified. E~288~ and L~294~ are required as *HLA-DRB1\*03*:*01* anchor residues, while T~289~, D~290~, D~291~, and I~293~ are critical B.10 TCR interacting residues.](pone.0152720.g004){#pone.0152720.g004}

These data indicate that the mAQP4~281-300~ binds to the *HLA-DRB1\*03*:*01* molecule via the same anchor residues and is thus able to be presented on the MHC II molecule in *HLA-DRB1\*03*:*01* transgenic mice.

AQP4 residue 290 mediates recognition by the B.10 TCR {#sec013}
-----------------------------------------------------

With mAQP4~281-300~ being capable of being presented on the *HLA-DRB1\*03*:*01* molecule, we next examined whether the single amino acid mutation inhibited the contact with the hAQP4~281-300~ specific B.10 TCR. Utilizing the alanine-scanning peptides, it was possible to identify critical residues that are required for generating the cellular immune response against the peptide. In performing IFNγ and IL-17 ELISpot assays with lymph node cells restimulated with alanine screening peptides (**[Table 1](#pone.0152720.t001){ref-type="table"}**), E288A, T289A, D290A, D291A, I293A, and L294A were identified as critical amino acids for either the binding of the peptide to *HLA-DRB1\*03*:*01*, or interacting the AQP4~281-300~ specific T cell receptor (TCR). None of the other amino acids are required for either binding to *HLA-DRB1\*03*:*01* molecule, or recognition by the B.10 TCR.

Subsequently, utilizing a MHC binding assay, only the previously identified peptides E288A, T289A, D290A, D291A, I293A, and L294A were screened for their ability to bind to *HLA-DRB1\*03*:*01*. 288E and 294L were identified to be *HLA-DRB1\*03*:*01* anchor residues, and the remaining residues play a critical role in the contact between the peptide and B.10 TCR (**[Fig 4B](#pone.0152720.g004){ref-type="fig"}**). These observations suggest that the D to E mutation between hAQP4 and mAQP4 peptides prevent the activation of hAQP4-specific T cells against mAQP4~281-300~.

We did not observe Ig class switching in mice immunized with mAQP4~284-299~ against whole-length AQP4 protein (**[Fig 4C](#pone.0152720.g004){ref-type="fig"}**), substantiating our observation that immunization with mAQO4~284-299~ does not drive antigen-driven T cell activation and a T cell proliferative response.

Discussion {#sec014}
==========

In this investigation, we show that immunization with the immunogenic, hAQP4~281-300~ determinant in *HLA-DRB1\*03*:*01* Tg mice, while leading to an expansion of antigen-specific CD4^+^ T cells, an Ig isotype switch of anti-hAQP4~281-300~ antibodies, and a robust Th~1~ and Th~17~ immune response, does not lead to a clinical disease phenotype via active immunization or passive transfer of hAQP4~281-300~--specific CD4^+^ T cells. We also were unable to detect any evidence of electrophysiological anterior pathway pathology, or any evidence of CNS infiltration in our mouse model. It is conceivable that there may have been inflammatory infiltrates within the meninges of the brain and spinal cord. This was not assessed.

In summary, our data suggest that a single amino acid substitution between hAQP4 and mAQP4 is one possible reason why it will be challenging to establish an animal model of NMO in *HLA-DRB1\*03*:*01* transgenic mice. For induction of CNS autoimmunity, recognition of the cognate antigen by the host immune system is an absolute requirement \[[@pone.0152720.ref024], [@pone.0152720.ref028]\]. Within the pathogenic AQP4~281-300~, the glutamic acid (D) to aspartic acid (E) mutation results in the addition of a methyl group within the side chain of the AQP4~287~ residue in the murine peptide. Despite being the same polarity, the hAQP4~281-300~-specific TCR can differentiate between the human and the mouse peptides. This was corroborated with data showing that the AQP4~287~ residue was important for contact with the B.10 TCR rather than being a MHC II anchor residue. Furthermore, antigen recall with mAQP4~281-300~ in *HLA-DRB1\*03*:*01* mice immunized with mAQP4~281-300~ does not result in proliferation of CD4^+^ T cells. Likely, negative thymic selection for mAQP4~281-300~ specific CD4^+^ T cells occurs in these mice, and prevents active disease induction.

T cell mediated disease models of NMO will be necessary to fully understand the complexity of this disorder. Induction of a CNS inflammatory autoimmune disorder by active immunization of *HLA-DRB1\*03*:*01* TG mice with human hAQP4~281-300~ will be complex due to a single amino acid substitution.

It is also possible that hAQP4~281-300~, the dominant determinant of hAQP4 in *HLA-DRB1\*03*:*01 in vitro*, does not result in generation of encephalitogenic CD4^+^ T cells *in vivo*. This possibility has not conclusively been ruled-out.

The pathogenic role of T cells in this disorder remains critical despite these observations.

Methods {#sec015}
=======

Mice {#sec016}
----

The *HLA-DRB1\*03*:*01* transgenic mice was given to our laboratory by Dr. Chella David and was previously described in *Strauss et al* \[[@pone.0152720.ref030]\]. Briefly, transgenic mice were generated by co-injection of a HLADRoL genomic fragment and a *DRB1\*030113* gene fragment into (C57BL/6 x DBA/2) F1 C57BL/6 embryos, and backcrossed to B10 mice \[[@pone.0152720.ref030]\]. Subsequently, the *DRB1\*030113* gene was introduced into the class II-negative H2^q-/-^ strain (16) by mating the B10.M-DRBI\*0301 line with the B10.MHCII ^/-^ line. C57BL/6 mice were purchased from (The Jackson Laboratories, Bar Harbor, MN). All mice were bred and maintained in a pathogen free mouse colony at the University of Texas Southwestern Medical Center (UTSW) with accordance to the guidelines set forth by the National Institute of Health and our institution. All experiments pertaining to these animals are approved by the UTSW Institutional Animal Care and Use Committee (IACUC).

Proteins and peptides {#sec017}
---------------------

Whole-length AQP4 M1 protein was donated by Dr. William Harries of the Membrane Protein Expression Center & Center for Structures of Membrane Proteins Macromolecular Structure Group (UCSF, San Francisco, CA.

The twenty-amino acid-long synthetic hAQP4~281-300~ (EDNRSQVETDDLILKPG VVH), mAQP4~281-300~ (EDNRSQVETEDLILKPGVVH), the hAQP4~281-300~ immunogenic region-alanine-screening peptides described in [Table 1](#pone.0152720.t001){ref-type="table"}, and PLP~91-110~ (YTTGAVRQIFGDYKTTICGK) were generated by JPT Innovative Peptide Solutions, Berlin Germany. Alanine scanning peptides utilized in the MHC binding assay were biotinylated utilizing an EZ link NHS-Peg4-Biotinylation kit (Thermo Scientific) following the manufacturer's specifications.

Animal model {#sec018}
------------

To induce active EAE, 8--12 week old female *HLADRB1\*03*:*01* transgenic mice were anesthetized with tribromoethanol (®Avertin; Sigma Aldrich, St. Louis, MO) 250 mg/kg intraperitoneally (i.p.), and subsequently immunized subcutaneously with proteolipid protein (PLP)~91-110~ (100 μg/100 μl/mouse), hAQP4~281-300~, mAQP4~281-300,~ or whole-length hAQP4 protein (200 μg in 100 μl) emulsified in an equal volume of Complete Freund Adjuvant (CFA) \[[@pone.0152720.ref031]\] containing 8 mg/mL H37Ra *M*. *Tuberculosis* (Difco, BD, Franklin Lakes, NJ)) in each flank. At the time of immunization and 48 hours later, mice received an i.p. injection of 200 ng pertussis toxin (Ptx) in 200 μL PBS.

For the induction of EAE by adoptive transfer, lymph nodes (LN) of *HLADRB1\*03*:*01* transgenic mice immunized with hAQP4~281-300~ were removed, and single-cell suspensions were prepared. LN cells were cultured in RPMI 1640, supplemented with 5 x 10^−5^ M 2-mercaptoethanol, 2 mM glutamine, 100 μg/ml penicillin, 100 μg/ml streptomycin, 10% fetal calf serum (HyClone, Logan, UT), and stimulated with 25 μgs/ml hAQP4~281-300~ and 0.5 ng/ml IL 12 in a 24 well plate for 72 hours. 5x10^6^ cells per 200 μls phosphate-buffered saline (PBS) were washed with PBS, and naïve *HLADRB1\*03*:*01* mice were subsequently inoculated. Two independent experiments were conducted with a minimum of 3 mice per group for each treatment paradigm.

For all experiments, individual animals were observed daily based on the EAE clinical scoring system as follows: 0 = no clinical disease, 1 = loss of tail tone, 2 = mild paraparesis, 3 = paraplegia, 4 = hindlimb and forelimb paralysis, 5 = moribund or death. Observation of all experimental animals occurred at least twice daily, with documentation of the clinical score. The following interventions are cumulative: Once a mouse reached clinical score 2, moist chow was provided daily. At score 3, animal weights were recorded daily, and animals were euthanized if the weight loss was greater than 20% from baseline. When mice scored 4, the urinary bladder was palpate and manually expressed as needed, and affected animals were no longer housed with cagemates of a lower score. Furthermore, suitable nesting material was always be provided. Affected mice had to be euthanized if there is no improvement after 72 hours at score of 4. Animals were euthanized immediately upon observation of a score of 5, regardless of time to development. Euthanasia was performed by carbon dioxide narcosis. Cervical dislocation was always used as a secondary physical method. Death was confirmed by observing for lack of breathing, loss of heartbeat, glazed appearance to the eyes, and loss of limb movement.

Histology {#sec019}
---------

Following fixation in 10% buffered formalin, coronal sections of brain tissue, axial sections of spinal cord, and longitudinally-oriented optic nerves were processed and embedded in paraffin blocks. 4 μm sections were cut, mounted on Fisher Brand Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA), and stained with hematoxylin & eosin (Fisher Scientific).

For the Luxol Fast Blue stained-sections, 6 μm thick sections of paraffin-embedded tissue were cut on a rotary microtome and mounted on Fisher Brand Superfrost Plus glass slides (Fisher Scientific). The sections were deparaffinized and hydrated. Following heating of the sections in 0.1% Luxol Fast Blue (Sigma-Aldrich, St. Louis, MO) at 60°C for at least one hour, excess stain was rinsed off. They were then differentiated in 70% alcohol for 25 seconds and rinsed in distilled water. Next, the sections were evaluated under the microscopy and depending on the adequacy of differentiation they were subjected to an additional round of lithium carbonate, and an alcohol rinse.

Pupillometry {#sec020}
------------

The pupillary reflex of experimental mice were measured using the pupillometry system by Neuroptics Inc. (San Clemente, CA) previously described in *Husain et al \[[@pone.0152720.ref032]\].* Briefly, infrared cameras capture digital images of mouse pupils in darkness at a baseline level after sedation. After the baseline pupil size is determined, an intensity-calibrated light source emits a stimulus into one or both of the eyes and a custom program measures the pupil diameter designed to analyze pupil size, onset latency, constriction velocity, and response amplitude. The light stimulus consists of a flash of light at 2, 32, or 125 μWs.

T cell proliferation assay {#sec021}
--------------------------

Ten days post immunization of hAQP4~281-300~ or mAQP4~281-300~ of *HLADRB1\*03*:*01* transgenic mice not given Ptx, single cell suspensions were generated by isolating the LNs of the immunized mice. Utilizing the CellTrace Violet Proliferation kit^®^ (Thermo Fisher Scientific, Waltham, MA), CD4^+^ T cell proliferation against antigens was determined. Briefly, isolated 20x10^6^ LN cells were incubated at 37°C for twenty minutes with 5 μM CellTrace Violet in PBS. After incubation, cells were washed with RPMI media twice, then incubated in a 96-well-round bottom plate at 1x10^6^ cells per well with either against hAQP4~281-300~ (5 μg/ml, and 25 μg/mL), mAQP4~281-300~ (5 μg/ml, and 25 μg/mL), media, or ConA (1 μg/mL) then incubated for 96 hours. Post incubation, cells were washed with staining FACS buffer (4% Fetal Calf Serum (FCS) in PBS) two times, then the Fc receptors were blocked with anti-CD16/32 (BD Biosciences, Franklin Lakes, NJ) for 15 minutes at 4°C before staining with mAbs for 30 minutes at 4°C. Cells were stained utilizing the following monoclonal antibodies: CD3-PE-C7 (EBiosciences Cat.\#25-0031-82, San Diego, CA), CD4-APC (BD Biosciences Cat\#553051), FOXp3-PE (BioLegend Cat\#320019, San Diego, CA). A total of 50,000 cells per sample were collected. Data were acquired with a FACS-LSRII (BD Biosciences), and analyzed using FlowJo software (Tree Star, Ashland, OR).

Tetramer analysis {#sec022}
-----------------

The frequency of antigen specific CD4^+^ T-cells was assessed using a tetramer binding assay protocol provided by the Benaroya Research institute \[[@pone.0152720.ref033]\]. Briefly, lymph nodes were harvested, and a single cell suspension was generated. Cells were resuspended in media, and *HLADRB1\*03*:*01* tetramers loaded with hAQP4~284-298~, or empty *HLADRB1\*03*:*01* tetramer (Benaroya Research Institute, Seattle, WA) were added, and incubated for 90 minutes at 37°C and 5%CO~2~. Cells were then washed with FACS buffer and blocked with anti-CD16/CD32, and stained following the protocol for cell surface staining described above with anti-CD3 APC (17A2, Tonbo Biosciences, San Diego, CA) and anti-CD4-Pacific Blue (RM4-5, BD-Biosciences). Data was acquired with a FACS Canto RUO II Special Order (BD Biosciences), and data was analyzed using FlowJo software (Tree Star).

Enzyme-linked immunosorbent spot assay {#sec023}
--------------------------------------

The frequency of IFNγ, IL-17, and GM-CSF secreting CD4^+^ T cells were determined by ELISpot assay. Groups of three male *HLA-DRB1\*03*:*01* mice were inoculated in the inguinal and axillary regions with 100 μgs of hAQP4~281-300~ as described above without the addition of Ptx. On day 10, lymph nodes and spleens were collected to generate single cell suspensions. Next, cells (2.5--5.0x10^5^ cells/well) were incubated with a hAQP4~281-300~ (25 μgs/mL), mAQP4~281-300~ (25 μgs/mL), hAQP4~284-299~ (25 μgs/mL), hAQP4~66-79~ (25 μgs/mL), a single hAQP4 alanine peptide (25 μgs/mL), media only, or ConA (1μg/mL) for 48 hours in 96 well ELISpot plates (Millipore MultiScreen 96-Well Plates). Capture and detection of cytokines were accomplished by using monoclonal antibodies (eBiosciences) specific for mouse IFNγ (Clone AN-18 \[capture\] and R4-6A2 \[detection\]), IL-17(Clone eBio17CK15A5 \[capture\] and eBio17B7 \[detection\]), or GM-CSF (Clone MP1-22E9 \[capture\] and MP1-2231G6 \[detection\]). Spots were counted with an automated ELISpot plate reader (Bioreader 5000, Biosys, Karben/Germany).

MHC binding assay {#sec024}
-----------------

This assay was adapted from a protocol found in *Busch et al* \[[@pone.0152720.ref034]\]. Briefly, spleens isolated from naïve *HLADRB1\*03*:*01* transgenic mice were used to generate single cell suspensions. Then, 1x10^6^ splenocytes were incubated with either biotinylated hAQP4~281-300~, mAQP4~281-300~, or hAQP4~284-299~ alanine screening peptides at a concentration of 10μ/mL for 4 hours at 37°C in a 96-well plate. Post incubation, cells were washed two times with FACS buffer and stained for flow cytometry utilizing avdin-FITC (Biolegend) applying the previously described protocol. After staining cells with avidin-FITC, they were run through a Accuri C6 (BD) flow cytometer, or a BD FACSCalibur, and Flowjo was utilized to quantify the percentage of FITC positive cells. A potential delta between the control peptides (hAQP4~284-299~, and mAQP4~281-300~), and the alanine screening peptides is considered to be the result of the alanine substitutions.

Statistical Analysis {#sec025}
--------------------

For parametric tests, data were checked for normality by using the Kolmogorov--Smirnov test. Normally distributed values were compared using the unpaired two-sided Student *t*-test. Correlations between continuous and categorical variables were assessed using the Mann-Whitney U-test. All experiments were repeated at least twice. All statistical tests were 2-sided and p \< 0.05 indicated significance. All analyses were performed with Prism 5 (Graphpad, La Jolla, CA, USA).
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